Jochem de Graaf

Robeco Institutional Asset Management BV (RIAM) is the Netherlands-based asset management subsidiary of Robeco Europe NV, itself a subsidiary of ORIX Corp. (TYO: 8591, ADR: IX), a Japanese business conglomerate that started operations in 1964. Headquartered in Rotterdam, the firm was founded in 1929 and provides investment products and services to institutional and private clients through locations in Europe, the US, the Middle East and Asia. RIAM is a socially responsible investor which engages in active dialogue with the companies in which they invest about good corporate governance and subjects of environmental or social interest. Their product range encompasses fixed-income, equity and alternative investments.

NIBC Bank NV engages in the provision of investment banking and financial services. The firm offers advises on mergers, acquisitions, financial policy, and property financing, lending, leveraged finance, and derivatives. It provides asset financing to corporate lending, leveraged finance, oil and gas services, infrastructure, real estate, and shipping Sector. The company was founded in 1945 and is headquartered in The Hague, the Netherlands.

NV Limburgs Instituut voor Ontwikkeling en Financiering (LIOF) is a private equity & venture capital firm, a subsidiary of Government of the Netherlands founded in 1935. NV Limburgs Instituut voor Ontwikkeling en Financiering is headquartered in Maastricht, the Neterlands.

Van Lanschot Kempen NV (Broker) (Van Lanschot Kempen-Broker) is the broker-dealer division of Van Lanschot Kempen NV (AMS: VLK), a financial institution headquartered in Amsterdam, Netherlands. The firm was founded in 1903 and formerly known as Kempen & Co. NV. Van Lanschot Kempen-Broker provides securities broking to institutional investors, companies, financial institutions, (semi) public institutions, foundations and high net-worth individual clients.

Ten Management BV (TM) is an independent private equity investment firm located in Hertogenbosch, The Netherlands. Established in 2002, TM specializes in recovery management and acts as interim managers for distressed firms. They provide a combination of capital, as well as management, financial and legal expertise. TM is the fund investment manager of TransEquity Network.

Triodos Investment Management BV (Triodos Investment Management) is a private equity/venture capital firm subsidiary of Triodos Bank NV founded in 1980. The firm is headquartered is headquartered in Zeist, Netherlands.

FABPulous BV develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability. It offers ultra rapid plasma preparation platform that can make a defined dilution of plasma from a small volume of whole blood in seconds and integrated lateral flow IVD platform. The company’s tests provide diagnosis and benefit to the patient, as well as the healthcare sector, the insurance industry, governments and society in general. FABPulous was founded in 2008 and is headquartered in Maastricht, the Netherlands.

Brightlands Venture Partners is an independent regional venture capital firm headquartered in Brightlands, Netherlands. The firm was founded in 2004.

Regionale Ontwikkelingsmaatschappij InnovationQuarter BV (Innovation Quarter) is an independent venture capital firm headquartered in The Hague, the Netherlands. The firm was founded in 2013.

Stichting Allee Wonen provides housing on a non profit basis. It places a wide target group in accommodations specific to housing requirements such as costs, environment, and living space needs. The company was founded on December 11, 1916 and is headquartered in Breda, the Netherlands.

Venvest Participaties BV is an independent private equity firm with its headquarters in Oisterwijk, the Netherlands. It was founded in 2016.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Allero Therapeutics BV is a biopharmaceutical company, which engages in the development of immunotherapies. It focuses on the research and development pipeline with a focus on a celiac disease product and a food allergy product. The company was founded by Poul Sorensen, Emil Pot, Federico Grego, and Kees Leenhouts and is headquartered in Rotterdam, the Netherlands.